Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

NCT04809766 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Study terminated due to end of funding.

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions

BIOLOGICAL: Autologous Mesothelin-specific TCR-T Cells
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Bendamustine

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]